Paul Hopper (I actually wonder if he still holds any shares here from the ones issued and bought years ago. )
Has always stipulated that small biotechs don't have the distribution and sales team to go door knock and convince clinics to prescribe new drugs, nor do we have a large enough target market (in PTX-100) to warrent running any "Ask Your Doctor" ads in the US.
So as much as SYC likes to talk about Oz company bringing a drug to market themselves and implying PTX could be the first, there is good reason for it.
Even NEU partnered with NASDAQ listed Acadia Pharmaceuticals for their Rett syndrome treatment.
Ann: Continued promising results in PTX-100 TCL trial, page-59
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PTX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $33.01M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1191 | 4.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.1¢ | 1190 | 1 |
View Market Depth
| Last trade - 08.15am 04/11/2024 (20 minute delay) ? |
| PTX (ASX) Chart |
Day chart unavailable